Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

39.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
6.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Widespread DNA off-targeting confounds RNA chromatin occupancy studies.

Nature biotechnology·2026
Same author

Deconvoluting fibre type proportions from human skeletal muscle transcriptomics and proteomics data using FibeRtypeR.

The Journal of physiology·2026
Same author

Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report.

NPJ precision oncology·2026
Same author

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.

Cell death & disease·2026
Same author

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.

JCO precision oncology·2026
Same author

Synergistic inhibition of CHK1 and MUS81 to combat replication stress resistance in high-risk neuroblastoma.

Scientific reports·2025

Related Experiment Video

Updated: Apr 7, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.1K

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

Joachim Tetteh Siaw1,2,3, Arne Claeys1,2,3, Wei-Yun Lai3

  • 1Department of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.

Iscience
|April 6, 2026
PubMed
Summary

Targeting RUVBL1 and RUVBL2 proteins shows promise for treating high-risk neuroblastoma by reducing MYC(N) signaling and inducing cell death. These RUVBL genes are also identified as potential biomarkers for patient prognosis.

Keywords:
biological sciencesmolecular biologymolecular neuroscienceneuroscience

More Related Videos

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

10.1K
Nucleofection of Rodent Neuroblasts to Study Neuroblast Migration In vitro
11:32

Nucleofection of Rodent Neuroblasts to Study Neuroblast Migration In vitro

Published on: November 12, 2013

11.9K

Related Experiment Videos

Last Updated: Apr 7, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.1K
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

10.1K
Nucleofection of Rodent Neuroblasts to Study Neuroblast Migration In vitro
11:32

Nucleofection of Rodent Neuroblasts to Study Neuroblast Migration In vitro

Published on: November 12, 2013

11.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • High-risk neuroblastoma features MYCN amplification and poor prognosis, necessitating novel therapeutic strategies.
  • Directly targeting MYC proteins has proven challenging, shifting focus to alternative targets like ATR in DNA damage response.
  • ATR inhibitors are being explored for neuroblastoma, with potential off-target effects or associated pathways needing investigation.

Purpose of the Study:

  • To investigate the role of RUVBL1 and RUVBL2 in MYCN-driven neuroblastoma.
  • To evaluate the therapeutic potential of inhibiting the RUVBL complex in neuroblastoma.
  • To identify RUVBL genes as prognostic biomarkers in human neuroblastoma.

Main Methods:

  • Transcriptomic analysis of MYCN-driven mouse tumors treated with ATR inhibitors.
  • Pharmacological inhibition of the RUVBL1/RUVBL2 complex using small molecules.
  • Assessment of MYC(N) signaling, cell-cycle progression, DNA damage, and apoptosis.
  • Validation of RUVBL gene association with MYCN and prognostic significance in human neuroblastoma datasets.

Main Results:

  • A significant RUVBL1 and RUVBL2 gene expression signature was identified in MYCN-driven tumors treated with ATR inhibitors.
  • Pharmacological inhibition of the RUVBL complex effectively reduced MYC(N) signaling, induced cell-cycle arrest, DNA damage, and apoptosis.
  • The RUVBL proteins were confirmed to associate with MYCN.
  • RUVBL1 and RUVBL2 were identified as independent prognostic biomarkers in human primary neuroblastoma.

Conclusions:

  • The RUVBL1/RUVBL2 complex is a critical mediator in MYCN-driven neuroblastoma and a viable therapeutic target.
  • Inhibiting the RUVBL complex offers a promising strategy for treating high-risk neuroblastoma.
  • RUVBL genes serve as valuable prognostic biomarkers for neuroblastoma patients.